Navigation Links
Newly Discovered Compound Blocks Known Cancer-Causing Protein

Duke Comprehensive Cancer Center scientists have discovered a potential new drug that inhibits destructive cell signals that drive the growth of one-third of all cancers. The scientists showed they could block the growth of cultured colon cancer cells using this new compound, called cysmethynil.

Their finding, reported in the March 22, 2005, issue of Proceedings of the National Academy of Sciences, is the first step toward developing a new class of anti-cancer drugs that block the Icmt protein from activating uncontrolled cell growth, a hallmark of cancer, according to Patrick Casey, Ph.D. Casey is the study's senior investigator and Duke pharmacologist and cancer biologist.

Moreover, said Casey, their discovery is the first to emerge from the Duke Small Molecule Screening Facility, which houses a library of more than 13,000 compounds available for screening promising drugs with potential to fight cancer and other diseases. Using automated robotics, the facility provides the kind of drug discovery capability usually available only to pharmaceutical company scientists.

Duke's new facility is a finalist for one of six $9 million National Institutes of Health (NIH) grants that will create a national network of publicly accessible small molecule facilities and make them available to researchers nationwide.

Duke University has filed a patent application for cysmethynil, Casey said, and intends to shepherd it through the first steps of drug development by testing the compound in animal models of cancer.

The research was supported by grant from the NIH and a Howard Hughes Medical Institute predoctoral fellowship to Casey graduate student Ann M. Winter-Vann, the first author of the study.

"This is the first selective small molecule inhibitor of Icmt, a protein that has been shown to be an important player in keeping a cancer-causing gene called 'Ras' turned on inside cells," said Casey.

Ras is a normal genetic component of the cell, but mutations in the gene can cause it to become stuck in an "on" position, promoting uncontrolled cell growth. Mutations in Ras that permanently activate it have been found in half of all colon cancer and 90 percent of pancreatic cancers, among other cancers.

Casey and his colleagues in Duke's Department of Pharmacology and Cancer Biology have already discovered and developed another class of cancer drugs aimed at inhibiting the processing pathway --the prenylation pathway ?that regulates Ras.

Several years ago, Casey's laboratory was one of a handful to unravel how the prenylation pathway works. This accomplishment led pharmaceutical companies to test compounds that block another key player in the pathway, a protein called farnesyltransferase. Blocking this protein inhibits Ras' ability to send growth-promoting signals inside cells. Several such compounds have shown promise in treating leukemias and lymphomas and are now under consideration for final approval by the U.S. Food and Drug Administration.

Since that time, Casey and his colleagues have been studying another key player in the pathway, the Icmt enzyme. Icmt adds a chemical tag called a "methyl group" to Ras. This methyl tag enables Ras to be directed to its final destination in the cell, from where it can send signals for unchecked growth.

"Ras needs to be at the plasma membrane in order to function," he said. "By preventing Icmt from adding a methyl group, we can effectively shut down Ras' ability to function, stopping it from sending signals for uncontrolled growth."

Initial experiments showed that knocking out the Icmt protein using genetic targeting also inhibited Ras, so the scientists decided to search for an effective and specific molecule that could inhibit Icmt function.

"We were looking for a small molecule that inhibited this enzyme specifically, without interfering with the normal regulation of the cell," said Casey. "What we found was a series of 30 structurally related molecules, and we selected the one with the highest potency ?that is cysmethynil."

Once the scientists had identified cysmethynil, they worked with Duke chemist Eric Toone and chemistry graduate student David Gooden to synthesize the molecule and verify its chemical structure. A search of the chemical literature turned up no previous description of the chemical, leading the scientists to believe they had discovered a new chemical compound with a unique biological function.

When the scientists tested the compound's ability to inhibit Ras function in living cells, they found it blocked the ability of colon cancer cells to grow independently in soft agar, a typical test of the cancerous
potential of cells.

"The next step is to test cysmethynil in animal models," said Casey. "We don't know how the compound will be metabolized in living animals, but we are encouraged by our initial results."

Other Duke scientists contributing to the research are Rudi A. Baron, Waihay Wong, June dela Cruz, and John D. York.


'"/>

Source:DukeMedNews


Related biology news :

1. Newly-discovered class of genes determines ?and restricts ?stem cell fate
2. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
3. Newly discovered pathway might help in design of cancer drugs
4. Newly Discovered Branding Process Helps Immune System Cells Pick Their Fights
5. Newly discovered protein an important tool for sleeping sickness research
6. Newly discovered genetic disease sheds light on bodys water balance
7. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
8. Newly recognized gene mutation may reduce seeds, resurrect plants
9. Newly discovered birdlike dinosaur is oldest raptor ever found in South America
10. Fitting in: Newly evolved genes adopt a variety of strategies to remain in the gene pool
11. Newly identified mechanism helps explain why people of African descent are more vulnerable to TB
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... Avanade is helping Williams Martini Racing, one of ... biometric data in order to critically analyse every aspect ... against their rivals after their impressive, record-breaking pit stop ... with Williams during the 2016 season to capture and ... rate, temperature and peak acceleration) for key members of ...
(Date:12/6/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, and the Prison ... (5) year funding commitment by Securus to PEP ... and reentry support to more inmates and their ... the Prison Entrepreneurship Program (PEP) is an independent ...
(Date:11/30/2016)... Nov. 30, 2016 Not many of us realize that we spend ? ... so we need to do it well. Inadequate sleep levels have been found to ... stroke, diabetes, and even cancer. Maybe now is the best time to ... help them to manage their sleep quality? Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... Regen BioPharma Inc. (OTCQB: RGBPP) In a recent ... team of scientists in Guangzhou, China ... of NR2F6 in patients with early cervical cancer correlates with ... cancer tissue as well as in the normal tissue surrounding ... study and the first that I am aware of that ...
(Date:12/7/2016)... ... ... Dwyer Dodge grew up hearing stories of the sea monster her father pulled from the ... turtle entangled in the lines of one of his lobster pots. He freed it and ... could remember ever seeing one so large so close to shore. After a couple of ...
(Date:12/6/2016)... ... ... Discovering new clues to natural treatments that could allow our bodies to ... And searching for keys to our immune systems by studying parasite-resistant fish. These are ... Edith and Peter O’Donnell Awards by The Academy of Medicine, Engineering and ...
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 ... of Santosh Kesari , MD, PhD, FANA, FAAN ... his experience in neurology and clinical trials to assist ... for treatment of stroke. The AmnioStem product is a universal ... previously shown therapeutic activity in animal models of stroke ...
Breaking Biology Technology: